Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    MITHRA Metals Highlights Its Role in Bridging the GCC Mining Investment Gap at The Mining Show 2026

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026
    Facebook X (Twitter) Instagram
    Iraq HeraldIraq Herald
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Iraq HeraldIraq Herald
    Home » Cambridge Isotope Laboratories, Inc. (CIL) Announces Relocation of Corporate Headquarters and Expansion of Research & Development and cGMP Production
    ACCESS Newswire

    Cambridge Isotope Laboratories, Inc. (CIL) Announces Relocation of Corporate Headquarters and Expansion of Research & Development and cGMP Production

    March 15, 20243 Mins Read

    New Location Positions CIL for Product Development and Future Growth

    TEWKSBURY, MA / ACCESSWIRE / March 15, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), has announced it will be relocating and expanding its corporate headquarters to newly purchased space in Tewksbury, MA, to advance the operations and growth of the company. The purchase was made in June 2023.

    The new location is a two-building, 150,000-square-foot campus with 25 lakefront acres at 100 & 200 Ames Pond Drive. The Ames Pond campus will be the home of a new 8,000-square-foot research and development (R&D) facility and will significantly expand cGMP, QC, formulations, and production labs. The spacious facility will provide CIL with the opportunity to cultivate a dynamic work environment for its valued employees, enabling cross-functional teams to collaborate seamlessly.

    “Stable isotope-labeled compounds are in high demand in the market. This expansion provides CIL the space to develop new products and invest in advanced analytical and production technologies,” states CIL’s Chief Science Officer (CSO) Todd Osiek. “The new R&D facility will include organic chemistry space as well as a development/scale-up lab with multiple walk-in hoods.”

    The GMP facility will more than double the existing space. Marwan ElMasri, Director of GMP Production, adds, “With this expansion, CIL will be able to produce metric ton quantities of commercial-grade APIs labeled with stable isotopes. This expansion will dramatically improve our capabilities for producing larger scale stable isotope-labeled materials for clinical trials. Our increased production capacity will certainly enable us to better serve our customers and partners.”

    CEO Cliff Caldwell adds, “The Ames Pond development, in addition to providing a highly desirable work campus for our employees, elevates our research and development efforts, significantly expands our GMP production capacities, improves operational efficiency, and enhances our ability to innovate for our customers.”

    CIL will continue operating its existing headquarters at 3 Highwood Drive, Tewksbury, MA, and production facility located 50 Frontage Road in Andover, MA. The 3 Highwood Drive facility will transition to Ames Pond as construction is completed. CIL’s Andover production location will remain operational after the move.

    About Cambridge Isotope Laboratories, Inc.

    CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

    Contact Information

    Crissy Krisko
    crissyk@isotope.com
    1.978.269.1930

    SOURCE: Cambridge Isotope Laboratories, Inc.

    View the original press release on newswire.com.

    Share. Facebook Twitter Pinterest LinkedIn Telegram Reddit Email

    Related Posts

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Chervon Names Doug Palmer Vice President of Finance – Canada

    November 5, 2026

    Chervon Promotes Soobia Haroon to Vice President, Human Resources – NA

    November 2, 2026

    Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 2026

    October 26, 2026

    Chervon Names Maggie Jones Director of National Field Sales OPS

    October 26, 2026

    GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production

    October 23, 2026
    Editor's Pick

    Botswana reviews proposed 33% power tariff hike today

    November 19, 2026

    The state energy regulator has officially initiated a comprehensive public review process regarding a substantial electricity rate increase requested by the national utility provider. Confirming the scope of this critical regulatory review, Botswana opens consultations on proposed 33 percent power

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Petrol price jump lifts South Africa inflation as SARB weighs rates

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    ASEAN signs digital economy pact eyeing $2 trillion by 2030

    November 18, 2026
    © 2026 Iraq Herald | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.